Clinical Impact Of Clonal Pseudomonas Aeruginosa In Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$547,238.00
Summary
In patients with cystic fibrosis (CF), the normal defence mechanisms are compromised by an inherent genetic fault which results in an extremely sticky and dehydrated mucus. The respiratory system is unable to eradicate microbes (infection) from the lungs of patients with CF which begin to multiply and cause infection and inflammation. Recurring infections are treated with multiple courses of antibiotics and frequent hospitalisation and eventually result in premature death. This study focuses on ....In patients with cystic fibrosis (CF), the normal defence mechanisms are compromised by an inherent genetic fault which results in an extremely sticky and dehydrated mucus. The respiratory system is unable to eradicate microbes (infection) from the lungs of patients with CF which begin to multiply and cause infection and inflammation. Recurring infections are treated with multiple courses of antibiotics and frequent hospitalisation and eventually result in premature death. This study focuses on the major bacterial problem, Pseudomonas aeruginosa. Several studies from Australia and the UK, including our own have shown that about 30% to 45% of patients share the same strain of Pseudomonas aeruginosa within a centre. We know that two dominant strains of Pseudomonas aeruginosa are found in CF centres on the eastern board of Australia. This is unexpected as this bacterium is usually acquired from the environment. The emergence of these clonal strains is causing increasing anxiety in the CF community. This study is designed to provide vitally needed information on the clinical implications of being infected by an clonal strain of Pseudomonas aeruginosa and the risk factors for the acquisition of an clonal strain. This new information will provide a rationale basis for the need for changes to infection control policies (including patient segregation), better outcome predictors for patients infected with clonal strain of Pseudomonas aeruginosa.Read moreRead less
Defining domains within Mycoplasma hyopneumoniae surface proteins that interact with host extracellular matrix: efficacy testing of candidate vaccines in swine. Over 90% of Australian commercial pig production facilities are affected by Mycoplasma hyopneumoniae, the causative agent of swine enzootic pneumonia. This disease causes economic losses in Australia of over $20 million per annum and up to $1 billion per annum in major swine rearing countries worldwide. This project will determine the p ....Defining domains within Mycoplasma hyopneumoniae surface proteins that interact with host extracellular matrix: efficacy testing of candidate vaccines in swine. Over 90% of Australian commercial pig production facilities are affected by Mycoplasma hyopneumoniae, the causative agent of swine enzootic pneumonia. This disease causes economic losses in Australia of over $20 million per annum and up to $1 billion per annum in major swine rearing countries worldwide. This project will determine the protective efficacy of new generation vaccines against M. hyopneumoniae, which aim to block the colonisation process and prevent disease .Read moreRead less
Identification and characterisation of Mycoplasma hyopneumoniae surface-molecules that interact with the host epithelium. Mycoplasma hyponeumoniae causes porcine enzootic pneumonia, a disease that significantly impacts swine production. Current vaccines are unable to prevent colonisation of the respiratory tract and are costly to produce and administer. The expression of microbial adhesins that mediate adherence to the extracellular matrix is considered the initial step in host colonisation for ....Identification and characterisation of Mycoplasma hyopneumoniae surface-molecules that interact with the host epithelium. Mycoplasma hyponeumoniae causes porcine enzootic pneumonia, a disease that significantly impacts swine production. Current vaccines are unable to prevent colonisation of the respiratory tract and are costly to produce and administer. The expression of microbial adhesins that mediate adherence to the extracellular matrix is considered the initial step in host colonisation for many bacterial pathogens. We propose to identify M. hyopneumoniae cell surface moleculaes that interact with components of the extracellular matrix. Targetting these cell surface molecules will lead to therapeutics that prevent disease and block colonisation, eventually eradicating the host pathogen from pig production facilities.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE200101832
Funder
Australian Research Council
Funding Amount
$425,941.00
Summary
Mechanisms of immune protection for infectious laryngotracheitis virus. This project aims to investigate the mechanisms of immune protection against infectious laryngotracheitis virus. This will be achieved by investigating the role of local and systemic immunity and the immune cells associated with long-term protection against disease. The mechanisms of protection against this virus remain unknown which impairs the development of efficacious vaccines. Expected outcomes of this project are a mor ....Mechanisms of immune protection for infectious laryngotracheitis virus. This project aims to investigate the mechanisms of immune protection against infectious laryngotracheitis virus. This will be achieved by investigating the role of local and systemic immunity and the immune cells associated with long-term protection against disease. The mechanisms of protection against this virus remain unknown which impairs the development of efficacious vaccines. Expected outcomes of this project are a more rational approach to vaccination resulting in the generation of more effective and safer vaccination strategies that should benefit our important poultry industry. Additionally, the new methodologies and knowledge on mucosal immune markers could be utilised for the study of other pathogens.Read moreRead less
A Randomised Controlled Trial Of Interventional Versus Conservative Treatment Of Primary Spontaneous Pneumothorax
Funder
National Health and Medical Research Council
Funding Amount
$412,315.00
Summary
Primary spontaneous pneumothorax (PSP) is a collapsed lung that occurs in otherwise healthy people without underlying lung disease. Current standard treatment is to insert a chest drain into the chest to remove the air around the collapsed lung so that the lung re-inflates rapidly ("interventional treatment"). We will determine whether doing nothing, i.e. letting the lung re-inflate slowly on its own over several weeks ("conservative treatment"), is just as good or even better for patients.
New antiparasitics to protect Australian livestock. There is an urgent need for new antiparasitics to treat multi-drug resistant livestock infections. This project aims to explore the bacteria and fungi present in the microbiomes of heavily infected sheep faeces and pastures, challenging them with environmental cues, including those from associated parasites, to stimulate production of defensive chemicals hidden deep within their genomes. Enabled by an integrated pipeline of high throughput anal ....New antiparasitics to protect Australian livestock. There is an urgent need for new antiparasitics to treat multi-drug resistant livestock infections. This project aims to explore the bacteria and fungi present in the microbiomes of heavily infected sheep faeces and pastures, challenging them with environmental cues, including those from associated parasites, to stimulate production of defensive chemicals hidden deep within their genomes. Enabled by an integrated pipeline of high throughput analytical cultivation, molecular networking, and chemical and biological analyses, expected outcomes include an enhanced ability to explore and exploit valuable chemistry hidden within microbial genomes, leading to the discovery of new classes of natural antiparasitic to safeguard livestock.
Read moreRead less
Targeting Fungal Phospholipid Metabolism For Antifungal Drug Discovery
Funder
National Health and Medical Research Council
Funding Amount
$828,557.00
Summary
Invasive fungal infections are a serious and escalating health problem. They cause severe disease with a high death rate and are very costly to the health system. New antifungal drugs with novel properties are needed now because there are problems with current drugs. This project aims to develop potent new antifungal drugs that are effective in many fungal diseases and are well-tolerated.
Optimisation of a novel hybrid vaccine for liver fluke disease in cattle. Optimisation of a novel hybrid vaccine for liver fluke disease in cattle. This project aims to optimise the formulation of novel fluke vaccine antigens by constructing combination hybrid recombinant antigens and using a protein adjuvant to improve immunogenicity, and test new antigens expressed in young flukes as vaccines and evaluate their ability to synergise with hybrid vaccines. Fasciola (fluke) infections cause seriou ....Optimisation of a novel hybrid vaccine for liver fluke disease in cattle. Optimisation of a novel hybrid vaccine for liver fluke disease in cattle. This project aims to optimise the formulation of novel fluke vaccine antigens by constructing combination hybrid recombinant antigens and using a protein adjuvant to improve immunogenicity, and test new antigens expressed in young flukes as vaccines and evaluate their ability to synergise with hybrid vaccines. Fasciola (fluke) infections cause serious economic losses to livestock production and fluke drug resistance threatens control, so new therapies such as a vaccine are needed. These vaccines should be evaluated in cattle trials. The major outcome plan is validation of hybrid antigens for commercial vaccine development for fluke control in cattle, leading to more sustainable beef and milk production in Australia.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0347223
Funder
Australian Research Council
Funding Amount
$100,000.00
Summary
Quantitative PCR facility for New England region of NSW. The project will deliver the first real-time PCR facility in the New England Region of NSW for use by University, CSIRO and Industry scientists. The facility will be based at the University of New England and be used by animal scientists, molecular biologists, parasitologists, immunologists and botanists at these institutions, in many cases in collaborative research projects. It will also support the training of seven PhD students and a po ....Quantitative PCR facility for New England region of NSW. The project will deliver the first real-time PCR facility in the New England Region of NSW for use by University, CSIRO and Industry scientists. The facility will be based at the University of New England and be used by animal scientists, molecular biologists, parasitologists, immunologists and botanists at these institutions, in many cases in collaborative research projects. It will also support the training of seven PhD students and a post-doctoral fellow. The facility will be unique to the region and will remove our current need to use facilities in Brisbane or Sydney.Read moreRead less
The COVID-19 pandemic has highlighted the risk of closed, indoor settings due to accumulation of aerosols generated from breathing, speaking, coughing or sneezing. Any airborne threat, whether an infectious virus or a chemical agent, will create a higher exposure in indoor settings. To mitigate this risk, using inter-disciplinary expertise, this research will improve preparedness, reduce health impacts of airborne threats, inform worker and occupant safety, building design and healthy futures.